Analys av Danske Bank efter delårsrapport kvartal 2, 2020
Handling the crisis well
Although the COVID-19 outbreak has (temporarily) held back Zenicor’s new s ale s and uncertainity is still high, the first month of Q3 offered an uptick in activity with a new large contract in the UK being signed. The majority of Ze nicor’s s ale s are recurring and the cost base has proven to be flexible, and we do not believe there should be any longterm negative effects once the pandemic crisis is over.
